Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + TPF
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Camrelizumab + TPF is a combination therapy consisting of the anti-PD-1 monoclonal antibody camrelizumab and a chemotherapy regimen known as TPF. Camrelizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 receptor (PD‑1) on immune cells, blocking its interaction with PD-L1 to enhance anti-tumor immune responses. The TPF regimen typically includes docetaxel, cisplatin, and either capecitabine or 5-fluorouracil; it acts by inhibiting cell division through multiple cytotoxic mechanisms. This combination has been studied as induction chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma (HNSCC), including hypopharyngeal squamous cell carcinoma and nasopharyngeal carcinoma. Camrelizumab is developed by Jiangsu Hengrui Pharmaceuticals and marketed in China under the brand name AiRuiKa for several cancers. The combination aims to improve response rates by leveraging both immunotherapy (camrelizumab) and cytotoxic chemotherapy (TPF)[1][2][3][4][6].
- Brand names
- AiRuiKa
- Other names
- camrelizumab + TPFcamrelizumab plus TPFcamrelizumab plus docetaxel, cisplatin, and capecitabinecamrelizumab plus docetaxel, cisplatin, and 5-fluorouracil (for classic TPF)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + TPF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + TPF.